Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25C | P30307 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7492893 | 0.87 | ALDH1A1 (0.48) | CDC25CALDH1A1L3MBTL1SMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL7487445 | 0.86 | ALDH1A1 (0.47) | CDC25CALDH1A1L3MBTL1SMN1; SMN2POLB | |
| SCHEMBL15347383 | 0.86 | CDC25C (0.57) | CDC25CALDH1A1L3MBTL1SMN1; SMN2GPR35 | |
| SCHEMBL25197556 | 0.85 | CDC25C (0.55) | CDC25CALDH1A1L3MBTL1SMN1; SMN2GPR35 | |
| SCHEMBL15483827 | 0.84 | POLB (0.56) | CDC25CALDH1A1L3MBTL1SMN1; SMN2GPR35 | |
| Hydrochloric Acid SCHEMBL7597150 | 0.83 | KMT2A (0.53) | CDC25CALDH1A1SMN1; SMN2HPGDTHRB | |
| SCHEMBL10417384 | 0.83 | L3MBTL1 (0.55) | CDC25CALDH1A1L3MBTL1SMN1; SMN2GPR35 | |
| SCHEMBL359377 | 0.80 | CDC25C (0.52) | CDC25CALDH1A1L3MBTL1SMN1; SMN2GPR35 | |
| SCHEMBL25206989 | 0.80 | CDC25C (0.54) | CDC25CALDH1A1CTSBKDM4ELMNA | |
| SCHEMBL15688012 | 0.80 | ALDH1A1 (0.49) | CDC25CALDH1A1SMN1; SMN2MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2022-02-15 | — | — | US | disclosed |
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2020-12-03 | — | — | US | disclosed |
| EP-3604306-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2020-02-05 | — | — | EP | disclosed |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| EP-1910321-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004959-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377520-A1 | MACROCYCLIC DERIVATIVE OF PYRAZOL[3,4-D]PYRIMIDIN-3-ONE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | WEE1, WEE2, PDPK1 | CDC25C 236/4885ALDH1A1 2614/4885L3MBTL1 4284/4885 |
| US-11248006-B2 | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof | WEE1, WEE2, PDPK1 | CDC25C 236/4885ALDH1A1 2614/4885L3MBTL1 4284/4885 |
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | CDC25C 1952/4885ALDH1A1 966/4885L3MBTL1 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.